Report: Sales of drugs approved this year could hit $18.7B in 5 years

11/14/2013 | American City Business Journals

A report from EP Vantage forecasts that the combined sales of 34 drugs expected to be approved in the U.S. this year could reach a record $18.7 billion by 2018, up 14% from the estimated five-year revenue of 43 drugs cleared last year. If approved before the year ends, Gilead Sciences' hepatitis C drug sofosbuvir will be the top revenue-generating drug with expected sales of $3 billion by 2018, followed by Biogen Idec's Tecfidera with $2.9 billion in potential sales.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA